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Metal Drugs for Multimodal Applications 
Christine O’Connor, 1 Luke O’Neill,2,4 Laura Perdisatt, 2 Samar Moqadasi,2 
Alan Casey,3 Qasim Mushtaq,3 Alessandra Ghion,1 Marcos Dias Pereira.4 
1School of Food Science and Environmental Health, DIT; 2 MSA lab, FOCAS Research 
Institute, DIT; 3Nanolab, FOCAS Research Institute, DIT;4 Depto de Bioquímica - Inst. 
Química Universidade Federal do Rio de Janeiro (UFRJ) 
Over the past decade a structured synthetic approach to the design and development of 
Ruthenium (II) polypyridyl complexes has been carried out at the DIT.1,2 Initial studies 
commenced with the design and synthesis of the ligands and the complexes themselves in the 
form of [Ru(L1)2L2]2+, where L1 is 2,2’-bipyridine, 1, 10-phenathroline or 2,2’-biquinoline 
and L2 is the main ligand with varying electronegativity properties. Ru (II) complexes are 
known to mimic iron in biological media and are really coming to the forefront in areas such 
as anticancer and antimicrobial applications.3-5 The photophysical characterisation of the 
complexes has been studied to determine a mechanism for optimising the luminescent yield 
and lifetimes of the complexes with the view of light activation applications in the future.6 
The regioisomer complexes of the L2 ligand and DNA intercalation studies were also carried 
out. 7 More recently the biological evaluation has commenced of the complexes and some 
promising results have been observed against certain cell lines. The most promising 
candidates have shown ROS activity, selectivity for A549 cell lines and activity against two 
strains of yeast cells (Saccharomyces cerevisiae) wild type (BY4741) and a deficient strain in 
superoxide dismutase 1 (sod1). At present the complexes are undergoing further mechanistic 
studies to determine their mode of action. In parallel to this work the complexes are also 
being investigated for their potential antimicrobial behaviour.  
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